Project Details
Description
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
| Short title | KRT-232-115 |
|---|---|
| Status | Active |
| Effective start/end date | 01.09.2025 → 28.02.2029 |
Fields of science
- 302024 Haematology
- 302055 Oncology
- 303 Health Sciences
- 304 Medical Biotechnology
- 305 Other Human Medicine, Health Sciences
- 302 Clinical Medicine
- 301 Medical-Theoretical Sciences, Pharmacy